What is ProfoundBio?
ProfoundBio operates at the intersection of biotechnology and oncology, focusing on the development of innovative antibody-based therapeutics. The company's core value proposition lies in its ability to translate complex scientific research into clinical-stage assets with curative potential. By leveraging proprietary technology platforms, the firm addresses a broad spectrum of tumor types, positioning itself as a high-potential player in the precision medicine landscape. Its market position is bolstered by a robust pipeline that spans discovery to advanced clinical trials, reflecting a sophisticated R&D strategy designed to meet significant unmet medical needs in the global cancer treatment market.
How much funding has ProfoundBio raised?
ProfoundBio has raised a total of $247M across 3 funding rounds:
Other Financing Round
$10M
Series A
$125M
Series B
$112M
Other Financing Round (2021): $10M with participation from Xianfeng Qiyun
Series A (2022): $125M led by Oriza, Sequoia China, and Lilly Asia Ventures
Series B (2024): $112M supported by RA Capital Management, Janus Henderson Investors, Ally Bridge Group, and Nextech Invest
Key Investors in ProfoundBio
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing their internal TechAtlas think tank to analyze clinical data.
Janus Henderson Investors
A global investment management firm providing institutional-grade financial solutions through disciplined research and a commitment to long-term outcomes in evolving market conditions.
Ally Bridge Group
A global firm specializing in high-impact life science innovation, managing significant transactions to address unmet medical needs through a blend of scientific research and financial expertise.
What's next for ProfoundBio?
With the recent influx of capital, ProfoundBio is expected to prioritize the advancement of its lead clinical candidates and the expansion of its internal R&D capabilities. The strategic focus will likely shift toward accelerating patient enrollment in ongoing trials and strengthening its intellectual property portfolio. As the company matures, the emphasis will remain on achieving key clinical milestones that validate its therapeutic platforms, potentially setting the stage for future strategic partnerships or further enterprise-level financing. The firm's ability to maintain its momentum in the competitive biotherapeutics sector will be contingent upon the successful execution of its clinical development roadmap and the continued support of its institutional investor base.
See full ProfoundBio company page
